Storage Stability
Thymosin alpha 5 (Ta5) is an acidic polypeptide thymic hormone fragment isolated from calf thymus, distinct from thymosin alpha-1 (Ta1). It has broader immunomodulatory activity than Ta1, restoring both T cell-dependent and T cell-independent immune functions, and has been studied as an immunomodulatory agent in immunodeficiency states and as a vaccine adjuvant with complementary but not identical activity to thymosin alpha-1.
Mechanism of Action
- Restores T cell marker expression (Thy-1, Lyt antigens) on null thymocytes and peripheral T lymphocyte precursors (broader activity than Ta1)
- Enhances T cell-dependent antibody responses and restores delayed-type hypersensitivity responses in immunodepressed animals
- Stimulates NK cell cytotoxicity via induction of IL-2 and IFN-gamma production from helper T cells
- Partially overlapping but distinct epitopes vs Ta1: Ta5 may restore some immune functions refractory to Ta1
- Adjuvant activity: enhances humoral and cellular vaccine responses when co-administered with vaccines
Research Findings
- Ta5 restored thymulin-like activity in neonatal thymectomized mice when Ta1 was only partially effective, demonstrating broader spectrum
- Ta5 enhanced antibody titers to T cell-dependent antigens (SRBC, KLH) in immunosuppressed mice by 2-4-fold vs untreated controls
- Ta5 + cyclophosphamide in tumor-bearing mice restored NK cell activity reduced by chemotherapy
- Less clinical study than Ta1 (thymalfasin); Ta1 has extensive hepatitis B/C and cancer clinical data; Ta5 remains mostly preclinical
- Structure-activity studies: the N-terminal region of Ta5 (aa1-7) shows distinct potency from Ta1 and may access unique TLR or receptor binding modes
Research Protocols
- Immunorestoration in mice: 10-100 mcg SC 3x/week for 4 weeks in thymectomized or chemotherapy-immunosuppressed mice
- NK cytotoxicity: 10-100 ng/mL Ta5 on ex vivo NK cell cultures from tumor patients; measure chromium-release killing
- Vaccine adjuvant: 10-50 mcg Ta5 SC co-administered with antigen in rodent vaccination model; measure IgG titers
- T cell differentiation: 1-100 nM Ta5 on bone marrow progenitors in thymulin induction assay
Interactions
- Thymosin alpha-1: partially overlapping but distinct activity; combination may provide broader immune restoration
- IL-2: Ta5 stimulates IL-2 production; IL-2-deficient states may be partially corrected by Ta5
- Cyclophosphamide/chemotherapy: Ta5 can partially restore immune function after myelosuppressive therapy
Safety Profile
Peptide thymic hormone. Well tolerated in animal studies. Limited human safety data vs thymosin alpha-1. No serious adverse effects reported in early human studies. No regulatory approval.
Legal & Regulatory
Research peptide; not approved as therapeutic (thymosin alpha-1/thymalfasin approved in China and some Asian countries for hepatitis)
Ready to dose Thymosin Alpha 5?
Get the exact syringe draw
You have read the research. Now run the math. Pick your vial size and BAC water volume, get IU draw in seconds.
Open the Calculator →
Categories:
Thymic HormoneImmunomodulatorEndogenous PeptideT Cell BiologyVaccine AdjuvantThymosin Family
More in Tissue Repair
View all →